enGene Holdings Past Earnings Performance
Past criteria checks 0/6
enGene Holdings's earnings have been declining at an average annual rate of -44.8%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-44.8%
Earnings growth rate
-21.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -53.1% |
| Net Margin | n/a |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How enGene Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 0 | -123 | 23 | 33 |
| 30 Apr 24 | 0 | -115 | 20 | 25 |
| 31 Jan 24 | 0 | -107 | 14 | 18 |
| 31 Oct 23 | 0 | -105 | 10 | 16 |
| 31 Jul 23 | 0 | -31 | 6 | 16 |
| 31 Oct 22 | 0 | -29 | 4 | 15 |
| 31 Oct 21 | 0 | -22 | 3 | 12 |
Quality Earnings: ENGN is currently unprofitable.
Growing Profit Margin: ENGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ENGN is unprofitable, and losses have increased over the past 5 years at a rate of 44.8% per year.
Accelerating Growth: Unable to compare ENGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ENGN has a negative Return on Equity (-53.12%), as it is currently unprofitable.